Table 1.
Demographics and clinical variables of patients with SJS/TEN from 2008 to 2021.
| Variable | % (mean or count) n = 77 |
|---|---|
| Age (years old) | 6–93 (45) |
| Menstrual status | |
| Premenstrual | 4% (3) |
| Menstruating | 45% (35) |
| post-menstrual/hysterectomy | 43% (33) |
| Sexual activity | |
| Yes | 17% (13) |
| No | 22% (17) |
| Not specified | 63% (48) |
| Diagnosis | |
| SJS | 55% (42) |
| TEN | 43% (33) |
| Extent of vulvovaginal involvement | |
| Vulvar involvement | 55% (42) |
| Vaginal involvement | 39% (30) |
| Gynecology consult | 43% (33) |
| Vaginal treatment recommendations (a) | 70% (21) |
| Dilator recommended | 70% (21) |
| Dilator used | 67% (20) |
| Steroid cream/ointment | 71% (30) |
| No vulvar treatment recommendations + | 19% (8) |
| Vulvar treatment recommendations (b) | 81% (34) |
| Gauze only | 19% (5) |
| Topical Steroid | 45% (19) |
| Other | 36% (15) |
| Menstrual suppression (c) | 49% (17) |
| Antifungal | 17% (13) |
(a) recommendation for vaginal dilator of the patients with documented vaginal involvement (n = 30). (b) Vulvar treatment recommendations of the patients with vulvar involvement (n = 42). (c) menstrual suppression of menstruating patients (n = 35).